A Comparison of Intracoronary with Intravenous Administration of Integrilin During Primary Percutaneous Coronary Intervention in Patients with acute ST-Elevation Myocardial Infarction: Clinical Outcomes

QUMS Deputy for Research0 个研究点目标入组 70 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Inclusion Criteria: an acute coronary syndrome with the indication for cardiac catheterization being ST-elevation myocardial infarction; coronary artery disease with a visually estimated stenosis of at least 75% in at least 1 epicardial vessel suitable for stenting; age 18 years; negative pregnancy test in women of childbearing potential; informed consent for participation in the trial

•multivessel PCI at the time of the index procedure or planned PCI within 30 days of the index procedure; severe coronary calcification; unprotected left main stenosis > 50%; target lesion in a saphenous vein graft; acute ST-elevation myocardial infarction after a primary PCI strategy; previous stenting at the target lesion; target lesion in an occluded vessel; deep vein thrombosis; presence of an inferior vena cava filter; a contraindication to GP IIb/IIIa inhibitor therapy (Hypersensitivity to eptifibatide or any component of the product; active abnormal bleeding within the previous 30 days or a history of bleeding diathesis; history of stroke within 30 days or a history of hemorrhagic stroke; severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding 6 weeks; current or planned administration of another parenteral GP IIb/IIIa inhibitor; dependency on hemodialysis).

发起方

QUMS Deputy for Research